Overview

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to identify an appropriate dose of study medication.
Phase:
Phase 2
Details
Lead Sponsor:
Alder Biopharmaceuticals, Inc.
CSL Behring